Preparing For A Future With Wyeth, Pfizer Posts Ho-Hum Q1 Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Although down, numbers are in line with expectations of the company and Wall Street.
You may also be interested in...
Pfizer’s Business Units Enable It To Be Nimble Even as It Grows
Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.
Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies
Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?